NCT06049134View on ClinicalTrials.gov

Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy

PHASE4RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 6, 2023

Primary Completion Date

March 1, 2026

Study Completion Date

August 1, 2027

Conditions

Lymphoma

Interventions

BIOLOGICAL

PCV20

Given by Injection into the muscle

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER